Poseida Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
9390 Towne Centre Dr Ste 200, San Diego,...Phone Number
(858) 779-3100Website
www.poseida.comRevenue
$54.7 MillionIndustry
About Poseida Therapeutics
Poseida Therapeutics Org Chart
Is Poseida Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Poseida Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Poseida Therapeutics has new funding data
Poseida Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Poseida Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Poseida Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Poseida Therapeutics
Product Launch: Get notified when Poseida Therapeutics launches new products
Click to see if Poseida Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Poseida Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Poseida Therapeutics
Compare insights from companies similar to Poseida Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Poseida Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Poseida Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Poseida Therapeutics.
Poseida Therapeutics financials insights
Gather financial insights about Poseida Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$23M
Private Equity
$11.2M
Unspecified
$19.8M
Series B
$30.5M
Series C
$142M
Series D
$110M
Stock Offering
$204.8M
Share Placement
$25M
Poseida Therapeutics Tech Stack
A closer look at the technologies used by Poseida Therapeutics
Most Recent Scoops
Poseida Therapeutics News & Media
Roche to complete acquisition of U.S. biopharma company Poseida
ZURICH (Reuters) -Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics , a specialist in complex immune cell therapies to treat several types of blood cancer. Roche said it has accepted for payment nearly 65 million shares in Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price of $9 per share, with an additional contingent paymentRoche purchases shares in tender offer for Poseida Therapeutics, Inc.
Basel, 8 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Blue Giant Acquisition Corp. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Poseida Therapeutics, Inc. (“Poseida”, NASDAQ: PSTX) at a price of $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain contingent payments ofPSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Poseida Therapeutics, Inc. (NASDAQ: PSTX) to Roche Holdings, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones, is fair to Poseida shareholders. Halper Sadeh encourages Poseida shareholders to click here to learn more aboutRoche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc. (Poseida) (NASDAQ: PSTX) at a price of $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain contingent payments of up to an aggregate of $4.00 per share in cash. The tender offer is being made pursuant to
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Poseida Therapeutics
Founded in 2014, Poseida Therapeutics is a biotechnology company that develops and discovers therapies for patients with high unmet medical needs such as blood and tumors cancer. Poseida. Poseida Therapeutics is located in California.... Read More